Capstone Investment Advisors LLC bought a new stake in Immunome, Inc. (NASDAQ:IMNM – Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 42,300 shares of the company’s stock, valued at approximately $1,044,000. Capstone Investment Advisors LLC owned approximately 0.07% of Immunome at the end of the most recent quarter.
Other large investors have also modified their holdings of the company. Avidity Partners Management LP acquired a new position in shares of Immunome in the fourth quarter valued at $14,268,000. Cerity Partners LLC acquired a new position in Immunome during the fourth quarter worth $656,000. Mayo Clinic acquired a new position in Immunome during the fourth quarter worth $1,161,000. Emfo LLC acquired a new position in Immunome during the fourth quarter worth $633,000. Finally, Jump Financial LLC acquired a new position in Immunome during the fourth quarter worth $172,000. 44.58% of the stock is currently owned by institutional investors and hedge funds.
Immunome Trading Down 0.7 %
Immunome stock traded down $0.09 during mid-day trading on Friday, hitting $12.03. The stock had a trading volume of 517,450 shares, compared to its average volume of 1,310,077. The stock has a 50-day simple moving average of $14.11 and a two-hundred day simple moving average of $17.16. The stock has a market capitalization of $721.43 million, a PE ratio of -1.59 and a beta of 1.79. Immunome, Inc. has a 12 month low of $6.13 and a 12 month high of $30.96.
Insiders Place Their Bets
In related news, Director Jean Jacques Bienaime bought 2,000 shares of Immunome stock in a transaction on Tuesday, May 21st. The shares were purchased at an average price of $13.57 per share, for a total transaction of $27,140.00. Following the completion of the acquisition, the director now owns 9,615 shares in the company, valued at $130,475.55. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 8.60% of the company’s stock.
Wall Street Analysts Forecast Growth
IMNM has been the subject of several recent analyst reports. Guggenheim initiated coverage on Immunome in a research note on Monday, April 15th. They set a “buy” rating and a $35.00 price objective for the company. Wedbush restated an “outperform” rating and issued a $33.00 target price on shares of Immunome in a research note on Tuesday, May 14th. JPMorgan Chase & Co. initiated coverage on Immunome in a research note on Tuesday, April 30th. They issued an “overweight” rating and a $24.00 target price for the company. Finally, Piper Sandler initiated coverage on Immunome in a research note on Friday, May 31st. They issued an “overweight” rating and a $27.00 target price for the company. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Immunome has a consensus rating of “Buy” and an average price target of $29.80.
Check Out Our Latest Stock Analysis on Immunome
Immunome Profile
Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.
Featured Articles
- Five stocks we like better than Immunome
- Consumer Discretionary Stocks Explained
- MarketBeat Week in Review – 7/1 – 7/5
- Dividend Payout Ratio Calculator
- Constellation Brands Stock Q1 2025: Crushing Anheuser-Busch?
- What Are Dividend Contenders? Investing in Dividend Contenders
- Qualcomm Stock Continues to Rise in the Face of Negative News
Receive News & Ratings for Immunome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunome and related companies with MarketBeat.com's FREE daily email newsletter.